EyeGene Inc Cash Flow-to-Debt Ratio
EyeGene Inc cash flow-to-debt ratio. EyeGene Inc (185490) has a Cash Flow-to-Debt Ratio of -0.23x as of March 2026, meaning its operating cash flow of ₩-3.13 Billion could theoretically repay 0% of its total liabilities (₩13.78 Billion) in one year. See EyeGene Inc (185490) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of EyeGene Inc (2014–2025)
Cash flow-to-debt ratio of EyeGene Inc from 2014 to 2025. Historical debt coverage capacity for EyeGene Inc across 12 annual periods. Check EyeGene Inc (185490) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
EyeGene Inc Cash Flow-to-Debt Ratio by Year (2014–2025)
EyeGene Inc cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for EyeGene Inc. For the full cash flow conversion analysis, see EyeGene Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.43x | ₩-5.98 Billion | ₩13.80 Billion | ▲ +46.6% |
| 2024 | -0.81x | ₩-12.17 Billion | ₩14.98 Billion | ▲ +44.3% |
| 2023 | -1.46x | ₩-20.07 Billion | ₩13.77 Billion | ▼ -7.2% |
| 2022 | -1.36x | ₩-18.57 Billion | ₩13.65 Billion | ▲ +27.4% |
| 2021 | -1.87x | ₩-30.00 Billion | ₩16.02 Billion | ▼ -505.3% |
| 2020 | -0.31x | ₩-9.75 Billion | ₩31.53 Billion | ▼ -5.1% |
| 2019 | -0.29x | ₩-8.32 Billion | ₩28.28 Billion | ▼ -20.7% |
| 2018 | -0.24x | ₩-7.48 Billion | ₩30.70 Billion | ▲ +76.5% |
| 2017 | -1.03x | ₩-6.76 Billion | ₩6.53 Billion | ▲ +59.0% |
| 2016 | -2.52x | ₩-5.99 Billion | ₩2.37 Billion | ▲ +11.8% |
| 2015 | -2.86x | ₩-4.48 Billion | ₩1.57 Billion | ▼ -102.1% |
| 2014 | -1.42x | ₩-2.39 Billion | ₩1.69 Billion | — |